Radio-opaque Contrast Agents for Liver Cancer Targeting With KIM During Radiation Therapy

Recruiting now

Conditions studied: Liver Neoplasm

In brief

This observational study will investigate the properties of image files standardly collected during radiation therapy treatment in a cross-section of liver cancer patients who received stereotactic ablative body radiation therapy (SABR) after trans-catheter arterial chemo emobilisation (TACE). Specifically, it will determine whether the radio-opaque contrast agents in the image files can be detected by tumour-tracking software (KIM).

Key facts

Study ID
NCT05169177
Run by
University of Sydney
People needed
50
Starts
2022-10-17
Expected to finish
2026-10-31
Last updated by the study team
2026-05-19

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

You may not qualify if…

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.